Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice

Patients with recurrent malignant glioma treated with bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), alone or in combination with irinotecan have had impressive reductions in MRI contrast enhancement and vasogenic edema. Responses to this regimen, as defined by a de...

Descripción completa

Detalles Bibliográficos
Autores principales: de Groot, John F., Fuller, Gregory, Kumar, Ashok J., Piao, Yuji, Eterovic, Karina, Ji, Yongjie, Conrad, Charles A.
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2010
Materias:
Basic and Translational Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2940588/
https://www.ncbi.nlm.nih.gov/pubmed/20167811
http://dx.doi.org/10.1093/neuonc/nop027

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2940588/
https://www.ncbi.nlm.nih.gov/pubmed/20167811
http://dx.doi.org/10.1093/neuonc/nop027

Ejemplares similares